170 related articles for article (PubMed ID: 8639913)
1. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
2. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
[TBL] [Abstract][Full Text] [Related]
3. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
5. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
6. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
7. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
Renner C; Ohnesorge S; Held G; Bauer S; Jung W; Pfitzenmeier JP; Pfreundschuh M
Blood; 1996 Jul; 88(1):236-41. PubMed ID: 8704179
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Hodgkin's disease with bispecific antibodies.
Hartmann F; Renner C; Jung W; Sahin U; Pfreundschuh M
Ann Oncol; 1996; 7 Suppl 4():143-6. PubMed ID: 8836426
[TBL] [Abstract][Full Text] [Related]
9. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
[TBL] [Abstract][Full Text] [Related]
11. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
[TBL] [Abstract][Full Text] [Related]
12. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies.
Renner C; Jung W; Sahin U; van Lier R; Pfreundschuh M
Eur J Immunol; 1995 Jul; 25(7):2027-33. PubMed ID: 7621876
[TBL] [Abstract][Full Text] [Related]
13. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
Arndt MA; Krauss J; Kipriyanov SM; Pfreundschuh M; Little M
Blood; 1999 Oct; 94(8):2562-8. PubMed ID: 10515858
[TBL] [Abstract][Full Text] [Related]
14. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
15. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
Demanet C; Brissinck J; De Jonge J; Thielemans K
Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
[TBL] [Abstract][Full Text] [Related]
18. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Hartmann F; Renner C; Jung W; Deisting C; Juwana M; Eichentopf B; Kloft M; Pfreundschuh M
Blood; 1997 Mar; 89(6):2042-7. PubMed ID: 9058726
[TBL] [Abstract][Full Text] [Related]
20. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice.
Kapp U; Düx A; Schell-Frederick E; Banik N; Hummel M; Mücke S; Fonatsch C; Bullerdiek J; Gottstein C; Engert A
Ann Oncol; 1994; 5 Suppl 1():121-6. PubMed ID: 7513537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
